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ABSTRACT
Introduction Ghana adopted the revised WHO 
recommendation on intermittent preventive treatment in 
pregnancy using sulfadoxine- pyrimethamine (IPTp- SP) in 
2012. This study has assessed the effectiveness and safety 
of this policy in Ghana.
Methods A total of 1926 pregnant women enrolled 
at antenatal care (ANC) clinics were assessed for birth 
outcomes at delivery, and placental histology results for 
malaria infection were obtained from 1642 participants. 
Association of reduced placental or peripheral malaria, 
anaemia and low birth weight (LBW) in women who 
received ≥4 IPTp- SP doses compared with 3 or ≤2 doses 
was determined by logistic regression analysis.
Results Among the 1926 participants, 5.3% (103), 
19.2% (369), 33.2% (640) and 42.3% (817) of women had 
received ≤1, 2, 3 or ≥4 doses, respectively. There was no 
difference in risk of active placental malaria (PM) infection 
in women who received 3 doses compared with ≥4 doses 
(adjusted OR (aOR) 1.00, 95% CI 0.47 to 2.14). The risk 
of overall PM infection was 1.63 (95% CI 1.07 to 2.48) in 
2 dose group and 1.06 (95% CI 0.72 to 1.57) in 3 dose 
group compared with ≥4 dose group. The risk of LBW 
was 1.55 (95% CI 0.97 to 2.47) and 1.06 (95% CI 0.68 
to 1.65) for 2 and 3 dose groups, respectively, compared 
with the ≥4 dose group. Jaundice in babies was present in 
0.16%, and 0% for women who received ≥4 doses of SP.
Conclusion There was no difference in the risk of PM, 
LBW or maternal anaemia among women receiving 3 
doses compared with ≥4 doses. Receiving ≥3 IPTp- SP 
doses during pregnancy was associated with a lower risk 
of overall PM infection compared with 2 doses. As there 
are no safety concerns, monthly administration of IPTp- SP 
offers a more practical opportunity for pregnant women to 
receive ≥3 doses during pregnancy.
INTRODUCTION
Malaria during pregnancy is a major public 
health problem that can lead to unfavourable 
pregnancy and birth outcomes such as abor-
tion, preterm delivery, stillbirth, maternal 
anaemia and low birth weight (LBW).1–3 In 
2018, an estimated 11 million of 38 million 
(29%) pregnancies were exposed to malaria 
in sub- Saharan Africa with 35% of pregnan-
cies in West Africa exposed to malaria during 
the same period.4
Key questions
What is already known?
 ► Malaria in pregnancy can lead to unfavourable pregnan-
cy and birth outcomes such as abortion, preterm de-
livery, stillbirth, maternal anaemia and low birth weight 
(LBW).
 ► Intermittent preventive treatment during pregnancy 
using 3 or more doses of sulfadoxine- pyrimethamine 
(SP) has previously been shown to be more effec-
tive than 2 or fewer doses in controlling malaria in 
pregnancy.
 ► The National Malaria Control Programme of Ghana 
has transitioned from a 3- dose intermittent preven-
tive treatment in pregnancy using SP (IPTp- SP) pol-
icy to the revised WHO policy, which recommends 
monthly administration of SP to pregnant women, 
starting early in the second trimester.
What are the new findings?
 ► Placental malaria was detected in 16.1%, 16.8%, 
10.4% and 9.7% of women who received ≤1, 2, 3 
or ≥4 IPTp- SP doses, respectively.
 ► Risk of placental malaria, LBW and anaemia were 
not different in women who received 3 doses com-
pared with ≥4 doses.
 ► Incidence of jaundice in babies was present in 0%, 
0.28%, 0.32% and 0% for women who received ≤1, 
2, 3 or ≥4 doses of SP, respectively.
What do the new findings imply?
 ► There is no added benefit to receiving more than 3 
doses of IPTp- SP. However, a monthly dosing sched-
ule would facilitate women receiving at least 3 doses 
of IPTp- SP recommended by the WHO.
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To prevent malaria during pregnancy, and the unfa-
vourable maternal and foetal outcomes associated with 
Plasmodium falciparum infections in areas of moderate 
to high malaria transmission, the WHO previously 
recommended the use of long- lasting insecticide- 
treated bednet (ITN), case management through 
prompt diagnosis and treatment as well as intermittent 
preventive treatment in pregnancy (IPTp) with at least 
2 full treatment doses of sulfadoxine- pyrimethamine 
(SP) given after quickening in the second and third 
trimesters and before 36 weeks of gestation at inter-
vals not less than 1 month.5 Effective IPTp, given at 
predetermined intervals during pregnancy, clears 
maternal parasitaemia and prevent subsequent rein-
fections.6 7 Ghana adopted this IPTp- SP policy in 2003, 
recommending that three tablets of SP should be 
given orally three times during pregnancy.8
The duration of the malaria prophylactic effect of 
SP has been reduced by the emergence of resistance 
to SP, for which reason it has been proposed that more 
frequent dosing may be needed.7 9 This supposition 
was supported by a meta- analysis of seven studies, 
which compared the efficacy of 2 doses to ≥3 doses 
of IPTp- SP9) and showed the latter to be more effi-
cacious. WHO policy on IPTp- SP was consequently 
revised and now recommends starting IPTp as early 
as possible in the second trimester, with administra-
tion at each scheduled ANC visit until the time of 
delivery, provided that the doses are given at least 
1 month apart. Ghana adopted this revised policy in 
2012.10 As a consequence of this change in policy, it 
has become possible for women to receive as many as 
six doses of SP during pregnancy, but the efficacy and 
safety of >3 doses of IPTp- SP have not been rigorously 
investigated. This study has, therefore, been under-
taken to evaluate the impact of additional SP doses 
on PM, other malaria indicators, birth outcomes and 




This study was conducted in three different ecolog-
ical zones of Ghana. The Dodowa area in the Greater 
Accra Region is in the forest- coastal savannah zone; 
Kintampo area in the Bono East Region is in the tran-
sition forest- savannah zone; Navrongo, in the Upper 
East Region, is in the Guinea savannah zone. Malaria 
transmission is low and perennial in the forest- coastal 
savannah zone,11 high and perennial in the transi-
tional forest savannah zone12 and high but seasonal in 
the guinea savannah zone.13 The study was carried out 
between March 2017 and September 2019.
Study design
This was a prospective, observational, cohort study of 
pregnant women who attended ANC in the three study 
sites. The study evaluated the effectiveness and safety of 
four or more doses of IPTp- SP on malaria in pregnancy 
and its consequences. The primary endpoint was active 
PM infection and secondary endpoints were overall PM 
infection, maternal anaemia, LBW, maternal peripheral 
blood malaria parasitaemia, placental blood and cord 
blood parasitaemia and maternal and fetal outcomes at 
delivery. Women of any gravidity attending an ANC who 
were aged 18 years and above with an intention to deliver 
in a health facility were eligible to join the study. Women 
with serious illness requiring hospitalisation, known HIV 
infection or known full deficiency of glucose-6- phosphate 
dehydrogenase, were excluded.
Sample size
The prevalence of active PM infection within the middle 
belt of Ghana in 2013 was 7.4%.14 Although this preva-
lence could have changed, it represents the best esti-
mate for active PM in this part of the country where the 
majority of the women was enrolled. To detect a reduction 
in active P. falciparum PM infection from 7.4% to 3.4%, 
with a 0.05 level of significance and 80% power, a sample 
of at least 502 women who receive ≥4 doses of IPTp- SP 
compared with an equal number of those who received 
3 doses of IPTp- SP was required. Assuming a 10% loss to 
follow- up during the course of pregnancy, an additional 
50 women were needed for each group making a total 
of 1104 women required for the study (Open Epi Soft-
ware). Annual data from the study areas in 2015 and 2016 
showed approximately 50% of pregnant women received 
3 doses of IPTp- SP. There was, therefore, the need to 
increase the sample size by a minimum of 50% (ie, 552) 
to be able to achieve at least 502 participants at delivery 
for each group.
Figure 1 Flowchart of study.
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Enrolment procedures
Fieldworkers, laboratory personnel and midwives were 
trained on study procedures prior to commencement of the 
study. Informed consent was obtained from all eligible preg-
nant women and a structured questionnaire was completed 
as previously described.15 Gestational age was determined 
by midwives at the first ANC visit using the symphysis- fundal 
height measurement method16 and subsequently using the 
ultrasound technique. IPTp- SP was administered by nurses 
at ANC clinics, following the WHO- revised policy guidelines 
and SP administration was recorded in the participant’s 
antenatal book at each visit.
Delivery
At delivery, cord blood (5 mL) was collected, after 
clamping the umbilical cord, into a K2- EDTA tube 












N % N % N % N % N %
Study site
  Kintampo 1128 58.6 40 38.8 202 54.7 365 57.0 521 64.0
  Dodowa 404 21.0 34 33.0 105 28.5 159 24.8 106 13.0
  Navrongo 394 20.4 29 28.2 62 16.8 116 18.1 187 23.0
Age
  Mean (SD) 27.69 (6.01) 27.26 (6.62) 27.25 (6.28) 27.90 (6.02) 27.78 (5.78)
Age group
  18–24 years 647 33.6 40 38.8 141 38.2 202 31.6 264 32.4
  25–34 years 995 51.7 45 43.7 177 48.0 345 53.9 428 52.6
  ≥35 years 284 14.7 18 17.5 51 13.8 93 14.5 122 15.0
Level of education
  No education 425 22.1 25 24.3 103 27.9 141 22.0 156 19.2
  Primary 306 15.9 16 15.5 63 17.1 100 15.6 127 15.6
  Junior high 695 36.1 38 37.0 133 36.0 242 37.8 281 34.5
  Secondary or higher 500 25.9 24 23.3 70 19.0 157 24.5 250 30.7
Marital status
  Married/married before 1450 75.3 75 72.8 242 65.6 490 76.6 643 79.0
  Living together with man, unmarried 263 13.7 17 16.5 72 19.5 91 14.2 83 10.2
  Single, unmarried 213 11.0 11 10.7 55 14.9 59 9.2 88 10.8
Religious background
  Christian 1475 76.6 83 80.6 267 72.4 485 75.8 640 78.6
  Muslim 389 20.2 17 16.5 85 23.0 132 20.6 155 19.0
  Traditionalist 11 0.6 0 0.0 5 1.4 4 0.6 2 0.3
  Other 51 2.6 3 2.9 12 3.3 19 3.0 17 2.1
Household SES
  Poorest 386 20.0 27 26.2 96 26.0 129 20.2 134 16.5
  More poor 385 20.0 23 22.3 62 16.8 124 19.4 176 21.6
  Poor 385 20.0 20 19.4 78 21.1 113 17.7 174 21.4
  Less poor 385 20.0 19 18.5 73 19.8 138 21.6 155 19.0
  Least poor 385 20.0 14 13.6 60 16.3 136 21.3 175 21.5
Gravidity
  Primigravidae 436 22.6 29 28.2 89 24.1 133 20.8 184 22.6
  Secundigravidae 474 24.6 22 21.4 92 24.9 163 25.5 197 24.2
  Multigravidae 1016 52.8 52 50.5 188 51.0 344 53.8 433 53.2
ITN use
  Yes 1242 64.5 70 68.0 232 62.9 393 61.4 547 67.2
  No 684 35.5 33 32.0 137 37.1 247 38.6 267 32.8
ITN, insecticide- treated bednet; SES, socioeconomic status; SP, sulfadoxine- pyrimethamine.
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(Becton Dickinson, England) for determination of 
haemoglobin (Hb) concentration and malaria parasi-
taemia by microscopy. A placental biopsy (approximately 
2.5 cm3) was taken from the maternal side of the placenta 
within 1 hour of placental expulsion and placed in a prela-
belled bottle containing 50 mL of 10% neutral buffered 
formalin. Incisions were also made on the maternal side 
of the placenta and 0.5 mL of placental blood collected, 
using a Pasteur pipette, into an EDTA Microtainer tube 
(Becton Dickinson, England). A capillary blood sample 
(0.2 mL) was collected from the mother prior to delivery 
for malaria microscopy. All biological samples were trans-
ported in a cold box to the nearest clinical laboratory 
(Kintampo Health Research Centre, Navrongo Health 
Research Centre or Shai- Osudoku District Hospital) for 
processing. New- borns were weighed on a calibrated 
digital scale (Jactermac, Germany) to the nearest 0.1 kg 
within 24 hours of birth. Screening for congenital abnor-




Hb concentration was estimated using a validated ABX 
Pentra 60C+Haematology analyser (Horiba- ABX, Mont-
pellier, France) or a HemoCue 200+haemoglobinometer 
(HemoCue, Angelholm, Sweden) according to manu-
facturers’ operating instructions. Quality controls were 
performed to ensure quality of the results generated.
Malaria parasitaemia determination
Thick and thin malaria blood smears were prepared 
from peripheral, placental and cord blood and stained 
using standard procedures, as described previously.17 18 
Briefly, thick and thin blood smears were prepared on 
the same slide, air- dried and the thin smear fixed with 
absolute methanol. Both smears were stained with 10% 
Giemsa for 10 min and air- dried. Parasites were detected 
and counted in the thick smear when <100 parasites were 
seen in a high power field, otherwise, counting was done 
using the thin smear. Parasite density was calculated 
using absolute or, if white blood cell or red cell count was 
not available, using an assumed leucocyte (8 000/cm3) or 
erythrocyte (5 000 000/cm3) count. A slide was declared 
as negative when no parasites were seen after examining 
at least 200 high power fields. Slides were examined by 
two certified independent microscopists and by a third 
in cases of discordance between the two initial readers. 
Differences were resolved by taking the result of the third 
reader and that of the earlier reader who agreed with 
him/her and in case of positive slides the average para-
site density was used.
PM infection determination
Placental biopsies, placed in 10% neutral buffered 
formalin, were stored in an air- conditioned room and 
transported to the Pathology Department of the School of 
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of Ghana and processed as described previously.19 Briefly, 
biopsies processed and embedded in paraffin wax blocks 
were sectioned and two slides were stained with H&E 
and Giemsa stains and examined microscopically by a 
pathologist for the presence of malaria parasites and/
or pigment. Results were reported as no infection, acute 
infection, chronic infection or past infection, based 
on the Ishmail modification of Bulmer’s classification. 
Active PM infection was defined as the presence of either 
acute or chronic placental infection.20 As part of quality 
control, 10% of slides were examined by an independent 
pathologist and results compared with those of the first 
reader (online supplemental table 1).
Outcome definitions
Active PM infection was defined as the presence of malaria 
parasites in the placenta with or without the presence of 
pigment, while overall placental infection was defined as 
the presence of parasite and/or pigment.20 21 Maternal 
anaemia was defined as a Hb concentration <110 g/L.22 
LBW was defined as a singleton baby weighing <2.5 kg 
measured within 24 hours after birth; stillbirth as a 
delivery of a non- living fetus ≥28 weeks gestation; preterm 
delivery as a newborn with a gestational age <37 weeks at 
delivery. Neonatal anaemia was defined as a cord blood 
Hb concentration <125 g/L.23
Data management and statistical analysis
All data were recorded on structured questionnaires, 
checked for completeness, double- entered and verified 
using a database designed with C- Sharp application as 
front end and SQL- Server as back end. Statistical anal-
ysis was carried out using Stata V.15 (StataCorp, College 
Station, USA).
Uptake of IPTp- SP was grouped into ≤1, 2, 3 and ≥4 
doses. χ2 tests were used to explore the association between 
the characteristics of study participants at enrolment and 
the number of doses of IPTp- SP received. The association 
between the number of doses of IPTp- SP received and 
PM infection (past, acute, chronic, overall and active) 
and birth outcomes (preterm delivery, LBW, mode of 
delivery, delivery complication, congenital abnormali-
ties, neonatal jaundice, neonatal anaemia) were assessed 
using χ2 or Fisher’s exact tests, where applicable.
Logistic regression was used to assess the association 
between the number of doses of IPTp- SP received and 
active PM infection, overall PM infection, maternal 
peripheral malaria parasitaemia, maternal anaemia at 
delivery and LBW. In each regression model, together 
with number of doses of IPTP- SP received, univariate 
analyses with age, education, household wealth, marital 
status, gravidity, ITN use, malaria treatment in the past 
2 weeks and malaria treatment during pregnancy were 
performed first. Variables found in the univariates anal-
yses to be significant at 0.15 level of significance were 
included in the multivariate analyses. In the multivariate 
analyses, variables with a p value <0.05 were considered 
to be statistically significant. Active PM was found in only 
2.8% (46/1642) of the participants with histologically 
examined placental biopsies, while 2.9% (54/1886) of the 
participants had peripheral blood asexual P. falciparum 
Table 3 Crude and adjusted ORs of 2 doses of IPTp- SP versus 3 or more doses
Outcome variable
Unadjusted analysis Adjusted analysis*
cOR 95% CI P value aOR 95% CI P value
Maternal parasitemia
  2 doses 2.08 1.14 to 3.81 0.02 1.56 0.84 to 2.93 0.16
  ≥3 doses 1 1
Active placental infection
  2 doses 1.96 1.01 to 3.81 0.05 1.45 0.73 to 2.89 0.29
  ≥3 doses 1 1
Overall placental infection
  2 doses 1.82 1.29 to 2.57 0.001 1.58 1.08 to 2.29 0.02
  ≥3 doses 1 1
Maternal anaemia
  2 doses 1.32 1.03 to 1.70 0.03 1.19 0.92 to 1.54 0.18
  ≥3 doses 1 1
Low birth weight
  2 doses 1.72 1.14 to 2.58 0.01 1.52 0.99 to 2.32 0.05
  ≥3 doses 1 1
*Adjusted for age, education, household SES, marital status, gravidity, ITN use, malaria treatment in past 2 weeks and malaria treatment 
during pregnancy.
aOR, adjusted OR; IPTp- SP, intermittent preventive treatment in pregnancy using sulfadoxine- pyrimethamine ; ITN, insecticide- treated 
bednet; SES, socioeconomic status.
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infection at delivery. Consequently, in accounting for 
the bias associated with using logistic regression for rare 
events, the penalised likelihood approach, which reduces 
the small- sample bias in maximum likelihood estimation 
was used.24
Patient and public involvement
Patients or the public were not involved in the design, 
or conduct, or reporting, or dissemination plans of our 
research.
RESULTS
Characteristics of study participants
A total of 2454 pregnant women were screened for eligi-
bility and 93.5% (2292/2454) were enrolled. Delivery 
outcomes were obtained for 84.0% (1926/2292) and 
placental results were available for 85.3% (1642/1926) 
(figure 1). There was no difference in characteristics 
between participants with or without placental results 
(online supplemental table 2). At enrolment, 52.2% 
(1006/1926) and 47.8% (920/1926) of participants had 
gestational age determined using ultrasound and fundal 
height, respectively.
Among the participants with birth outcomes, those who 
had taken 0, 1, 2, 3 or ≥4 doses by the time of delivery 
were 0.7% (14), 4.6% (89), 19.2% (369), 33.2% (640) 
and 42.3% (814), respectively. Majority of the study popu-
lation, 58.6% (1128/1926) came from Kintampo area 
and 51.2% (978/1926) were aged between 25 and 34 
years. Primigravidae and secundigravidae formed 22.6% 
(435/1926) and 24.7% (475/1926) of the study popula-
tion, respectively, and 64.5% (1242/1926) had used an 
ITN the previous night (table 1). Only 29% (562/1926) 
of the women reported treatment for malaria during 
pregnancy while 11.6% (223/1926) reported receiving 
antimalarial treatment within 14 days prior to delivery. 
Characteristics of study participants by study area are 
presented in online supplemental table 3.
Impact of IPTp-SP on PM infection
The prevalence of overall PM among the 1642 placental 
biopsies examined histologically was 11.6% (95% CI 
10.2% to 13.3%). This comprised 2.8% active infections 
(1.8% acute and 1.0% chronic) and 8.8% past infections.
The prevalence of active placental infection was highest 
in women who received ≤1 dose (6.9%), followed by those 
who received 2 doses (4.1%) but the same, 2.2% in each 
case, among those who received 3 or ≥4 doses of IPTp- SP 
(table 2). In the univariate analysis, age, household socio-
economic status (SES), marital status, gravidity and the 
number of SP doses received during pregnancy were 
associated with active placental infection. In the multivar-
iate analysis, there was no difference in the risk of active 
PM infection among women who received 3 or ≥4 doses 
of IPTp- SP (adjusted OR (aOR) 1.00, 95% CI 0.47 to 
2.15) nor between those who received 2 versus ≥4 doses 
(aOR 1.48, 95% CI 0.69 to 3.18) (online supplemental 
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infection in women who received 2 doses compared with 
those who received ≥3 doses IPTp- SP (aOR 1.45, 95% CI 
0.73 to 2.89) (table 3).
Lower age, lower household SES, being single, primi-
gravid or secundigravid and receiving malaria treat-
ment during pregnancy were associated with overall PM 
infection in the univariate analysis. In the multivariate 
analysis, risk of overall PM infection was high in women 
aged <25 years compared with those aged ≥25 years (aOR 
1.77, 95% CI 1.18 to 2.65); the most poor household SES 
compared with the least poor (aOR 2.47, 95% CI 1.40 to 
4.35); primigravidae compared with multigravidae (aOR 
2.95, 95% CI 1.83 to 4.75) and those who received ≤2 
doses IPTp- SP compared with those who received ≥4 
doses (aOR 1.63, 95% CI 1.07 to 2.48) (table 4). The risk 
of overall PM infection was also higher in women who 
received 2 doses compared with those who received ≥3 
doses IPTp- SP (aOR 1.58, 95% CI 1.08 to 2.29) (table 3).
The overall prevalence of malaria parasitaemia in 
placental blood was 1.8% (25/1387). The prevalence 
of placental blood malaria was highest in women who 
received ≤1 dose (2.9%; 2/69) and lowest in those who 
received ≥4 doses (1.4%; 8/587). The number of IPTp- SP 
doses received during pregnancy had no impact on the 
prevalence of placental blood malaria.
The impact of IPTp-SP on maternal peripheral and cord blood 
malaria parasitaemia at delivery
Overall, the prevalence of peripheral blood asexual P. 
falciparum infection at delivery among study women 
was 2.9% (54/1886). Among women who received ≤1, 
2, 3 and ≥4 doses of IPTp- SP, the prevalence was 6.2% 
(6/97), 4.5% (16/357), 2.6% (16/627) and 2.0% 
(16/805), respectively, but differences between groups 
were not statistically significant. In the univariate anal-
ysis, age, household SES, number of SP doses received 
and malaria treatment during pregnancy were associated 
with a higher risk of maternal peripheral malaria parasi-
taemia at delivery. In the multivariate analysis, there was 
no difference in risk of peripheral malaria parasitaemia 
in women who received 3 or ≥4 doses of SP (aOR 1.29, 
95% CI 0.64 to 2.60) nor 2 doses versus ≥4 doses of SP 
(aOR 1.74, 95% CI 0.85 to 3.56). Being in a household 
of lower SES remained strongly associated with a risk of 
peripheral malaria parasitaemia (table 5). The overall 
prevalence of cord blood P. falciparum parasitaemia was 
0.4%, and 0% (0/74), 0% (0/294), 0.8% (4/503) and 
0.3% (2/643) among women who received ≤1, 2, 3 
and ≥4 doses of SP, respectively. There was no difference 
by number of IPTp- SP doses received.
Impact of IPTp-SP on maternal anaemia at delivery
The overall mean Hb concentration (SD) for study women 
at delivery was 11.5 (2.0) g/dL. Overall, the prevalence of 
maternal anaemia (Hb <11.0 g/dL) was 34.2%. The prev-
alence of anaemia by number of IPTp- SP doses received 
was 40.4% (40/90), 38.8% (130/335) 35.5% (206/581) 
and 30.0% (222/741) in women who received ≤1, 2, 3 
and ≥4 doses of IPTp- SP respectively.
In a univariate analysis, low household SES, being 
unmarried, receiving fewer IPTp- SP doses during preg-
nancy and having been treated for malaria (apart from 
SP) were associated with a higher risk of maternal 
anaemia at delivery (online supplemental table 5). In the 
multivariate analysis, the risk of anaemia was higher in 
women from most poor household compared with those 
from least poor households (aOR 1.51, 95% CI 1.09 to 
2.06) and women who received 2 IPTp- SP doses during 
pregnancy compared with those who received ≥4 doses 
(aOR 1.34, 95% CI 1.02 to 1.77). There was no statisti-
cally significant difference in risk of anaemia among 
women who received 3 doses compared with those who 
received ≥4 doses (aOR 1.24, 95% CI 0.99 to 1.56) (online 
supplemental table 5) and also in women who received 2 
doses compared with those who received ≥3 doses (aOR 
1.19, 0.92–1.54) (table 3).
Impact of IPTp-SP on LBW and other birth outcomes
Overall, 0.5% (10/1926) and 0.9% (17/1926) of preg-
nancies resulted in a miscarriage or stillbirth, respectively. 
The mean gestational age at delivery overall was 38.4 (SD 
2.5) weeks and increased significantly with an increase in 
the number of IPTp- SP doses received (table 6).
Mean birth weight for all live singleton deliveries was 
3.07 (SD 0.48) kg, and 2.84 kg, 2.99 kg, 3.09 kg and 
3.11 kg in babies of women who received ≤1, 2, 3, or ≥4 SP 
doses, respectively. The overall prevalence of LBW was 
7.5% (140/1856) and 17.9% (17/95), 10.2% (36/354), 
6.5% (40/615) and 5.9% (47/792) in babies of women 
who received ≤1, 2, 3 or ≥4 SP doses, respectively. Factors 
strongly associated with LBW in the univariate anal-
ysis were household SES, gravidity and the number of 
IPTp- SP doses received. In the multivariate analysis, the 
risk of LBW was higher in babies born to women of most 
poor households compared with those from least poor 
households (aOR 4.26, 95% CI 2.23 to 8.04), There was 
no difference in risk of LBW between babies of women 
who received 3 doses of SP and those who received ≥4 
doses (aOR 1.06, 95% CI 0.68 to 1.65) nor between those 
who received 2 doses and those who received ≥4 doses 
(table 7). The risk of LBW in babies born to mothers who 
received 2 doses of IPTp- SP did not differ significantly 
compared with those who received ≥3 doses (aOR 1.52, 
0.99 to 2.32) (table 3).
Impact of IPTp-SP doses on the safety of the baby
A low prevalence of jaundice, defined as yellowish color-
ation of the baby’s eyes (0.16%, 9/1899), was observed 
in the babies overall, with none in those born to women 
who received ≥4 doses of SP during pregnancy (table 6). 
The mean haemoglobin concentration in study babies 
overall was 14.53 g/dL and highest (14.62 g/dL) in 
the babies born to women who received ≥4 doses of SP 
during pregnancy, but with no significant differences 
between the groups. The overall prevalence of neonatal 
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anaemia was 15.4% (266/1731); 21.1% (19/90), 16.5% 
(55/333), 16.6% (96/580) and 13.2% (96/728) in babies 
of mothers who received ≤1, 2, 3 and ≥4 SP doses, respec-
tively (table 6). The overall prevalence of congenital 
abnormalities was 0.5% (9/1899) and there was no statis-
tical difference in the incidence of congenital abnormali-
ties by the number of IPTp- SP doses that the mother had 
received (table 6).
DISCUSSION
This observational, prospective cohort study demon-
strated a low prevalence of both active and overall histo-
logically confirmed PM infection in three ecological 
zones in the northern guinea- savannah, middle forest- 
savannah and southern forest- coastal- savannah zones of 
Ghana. Our finding of no statistically significant benefit 
of receiving ≥4 doses IPTp- SP over the standard 3- dose 
in Ghana against PM (active or overall), peripheral 
maternal malaria, LBW or maternal anaemia is consistent 
with findings in Zambia.25 26
The nearly two- fold risk of overall PM infection in 
women who received 2 doses compared with those who 
received 3 or more doses in the present study is consis-
tent with previous ones that reported 3 or more doses 
of IPTp- SP to be more effective in reducing PM than 2 
doses.27 The prevalence of active PM found in this study 
was lower than in the northern and middle zones of 
Ghana in 2013 and 2015, respectively, prior to implemen-
tation of the WHO monthly IPTp- SP policy.14 28 The prev-
alence of overall PM infection of 11.6% was lower than in 
the southern coastal (35.9%) and middle forest- savannah 
(37.5%) zones of Ghana, respectively, before introduc-
tion of the new policy. This marked reduction in the prev-
alence of PM infection could be attributed in part to high 
ITN use, use of other malaria prevention interventions as 
well as to a high uptake of IPTp- SP in the study cohort. A 
baseline study on the prevalence of malaria parasitaemia 
among pregnant women at first ANC visit in our study 
area in the middle belt of Ghana showed one- fifth of 
the women carried malaria parasites.15 The low malaria 
parasite prevalence reported in this study can further 
be reduced if IPTp- SP uptake continues to increase over 
time.
Contrary to findings in previous studies in Ghana29 30 
and elsewhere,2 9 this study showed no difference in risk 
of LBW in babies born to women who received 3 or more 
doses of IPTp- SP.
A major strength of this study is that unlike other 
studies that compared only ≥3 doses of IPTp- SP to 2 
doses, this study assessed the additional benefits or 
otherwise of receiving ≥4 doses of IPTp- SP. This is one 
of very few studies30 31 to evaluate the impact of the new 
WHO IPTp- SP policy and it was conducted in different 
ecological zones of Ghana with varied malaria transmis-
sion intensities, thereby producing generalisable results. 
A limitation of this study is that the study team was not 
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clinics, and consequently the number of doses of SP 
received was based on the number recorded in the ANC 
booklets of the pregnant women at the time of delivery. 
However, ANC nurses, who had previously been trained 
by the Ghana Health Service on administration of SP at 
the clinics, were given refresher training by the study team 
to ensure SP administration was directly observed at the 
clinic and accurately recorded in the women’s booklets. 
A second limitation is that the possible impact of higher 
numbers of ANC visits on pregnancy outcomes could not 
be considered during the analysis. Previous studies have, 
however, shown that women with higher numbers of ANC 
visits have better pregnancy outcomes.32 33 Third, there 
is also the possibility that there were some important 
confounders associated with the number of doses given 
that could not be detected and corrected for in the 
multiple regression analysis. Fourth, another important 
limitation in this study is the lack of randomisation. With 
the commencement of the revised WHO policy on IPTp- 
SP, it would have been unethical to assign participants 
to number of doses below the recommended number. 
This poses a risk for selection bias for which controlling 
was not possible. Another limitation was that multiple 
comparisons were done, so some statistically significant 
differences could have been found by chance. However, 
in general, the results were very consistent. Finally, even 
though no serious safety concerns were associated with 
monthly IPTp- SP dosing, this study was not powered to 
detect differences in safety indicators such as jaundice 
and congenital malformations, and measurement of 
serum bilirubin could have provided a more accurate esti-
mates than clinical jaundice. Bilirubin could, however, 
not be measured due to logistical constrains.
This study did not show significant additional benefits of 
receiving ≥4 doses compared with 3 doses IPTp- SP during 
pregnancy. Receiving 3 or more doses, however, showed 
a reduction in the risk of overall PM infection compared 
with 2 doses. The WHO policy of monthly administration of 
IPTp- SP to pregnant women in the second and third trimes-
ters remains a more practical way of ensuring adequate 
doses are received during delivery, instead of restricting the 
number of doses to a maximum of three.
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